APLS241220P26000
- 0.55
- -1.33-70.74%
Apellis Pharmaceuticals Newsroom
Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk
Astellas Receives Complete Response Letter From FDA for Izervay SNDA
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
Apellis Pharmaceuticals (APLS) Receives a Buy From Jefferies
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $32
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Apellis Pharmaceuticals: Strategic Advantage and Market Potential Boost With Syfovre's Competitive Edge
Hold Rating on Apellis Pharmaceuticals Amid Regulatory Setbacks and Market Uncertainties
Insider Sellers Might Regret Selling Apellis Pharmaceuticals Shares at a Lower Price Than Current Market Value
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Apellis Pharmaceuticals Analyst Ratings
UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $55
Earnings Call: Apellis Pharmaceuticals Q3 2024 Results Show Promise
Express News | RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y